Other
Standard systemic therapy
Standard systemic therapy is an intervention with 4 clinical trials. Currently 3 active trials ongoing.
Total Trials
4
Max Phase
—
Type
OTHER
Molecule
—
Success Metrics
Active Trials
3(75%)
Phase Distribution
Ph phase_3
2
50%
Ph not_applicable
1
25%
Ph phase_2
1
25%
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Recruiting3
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 21 (25.0%)
Phase 32 (50.0%)
N/A1 (25.0%)
Trials by Status
not_yet_recruiting125%
recruiting375%
Recent Activity
3 active trials
Showing 4 of 4
recruitingphase_3
Intraperitoneal Paclitaxel and Systemic Therapy Versus Systemic Therapy Alone in Gastric Cancer Patients With Peritoneal Metastasis
NCT07304271
not_yet_recruitingnot_applicable
Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone Metastases
NCT07687225
recruitingphase_3
Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease
NCT06141070
recruitingphase_2
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer
NCT06841159
Clinical Trials (4)
Showing 4 of 4 trials
NCT07304271Phase 3
Intraperitoneal Paclitaxel and Systemic Therapy Versus Systemic Therapy Alone in Gastric Cancer Patients With Peritoneal Metastasis
NCT07687225Not Applicable
Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone Metastases
NCT06141070Phase 3
Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease
NCT06841159Phase 2
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 4